Phosphogliv capsules, No. 50
Expiration Date: 11/2025
Russian Pharmacy name:
Фосфоглив капсулы, №50
Fatty liver degeneration (hepatosis), alcoholic, toxic, including medicinal, liver damage;
As part of the complex therapy of viral hepatitis (acute and chronic), liver cirrhosis and psoriasis.
It is taken orally, during meals, without chewing, with a small amount of liquid.
The recommended dosage regimen for adults and children over 12 years old is 2 capsules 3 times a day. The duration of use can be up to 6 months, on average - 3 months.
Active substances : Phospholipids (Lipoid C 80) (in terms of 100% substance) (main component phosphatidylcholine 73-79%) - 65 mg, sodium glycyrrhizinate (trisodium salt of glycyrrhizic acid) - 35 mg.
Excipients : microcrystalline cellulose - 141.2 mg, calcium carbonate - 204.7 mg, calcium stearate - 0.9 mg, talc - 7.7 mg, colloidal silicon dioxide (aerosil) - 5.5 mg, hard gelatin capsules - 96.0 mg [ body : sunset yellow dye (E110) - 1.0%, titanium dioxide (E171) - 1.0%, gelatin - up to 100.0%; cap : titanium dioxide (E171) - 0.2%, iron dye black oxide (E172) - 3.5%, gelatin - up to 100.0%].
Hypersensitivity to glycyrrhizic acid, phosphatidylcholine or other components of the drug;
Antiphospholipid syndrome;
Pregnancy (data on efficacy and safety are not enough);
Breastfeeding period (data on efficacy and safety are not enough);
Children under 12 years of age (efficacy and safety data are scarce).
With care .
In patients with portal hypertension. In patients with arterial hypertension. If you have these diseases, you should consult your doctor before taking the drug.
Tradename:
PhosphoglivЃ
Chemical name:
phosphatidylcholine + trisodium salt of glycyrrhizic acid.
Grouping name:
phospholipids + glycyrrhizic acid.
International non-proprietary name:
Dosage form:
capsules
Composition for one capsule.
Active substances : Phospholipids (Lipoid C 80) (in terms of 100% substance) (main component phosphatidylcholine 73-79%) - 65 mg, sodium glycyrrhizinate (trisodium salt of glycyrrhizic acid) - 35 mg.
Excipients : microcrystalline cellulose - 141.2 mg, calcium carbonate - 204.7 mg, calcium stearate - 0.9 mg, talc - 7.7 mg, colloidal silicon dioxide (aerosil) - 5.5 mg, hard gelatin capsules - 96.0 mg [ body : sunset yellow dye (E110) - 1.0%, titanium dioxide (E171) - 1.0%, gelatin - up to 100.0%; cap : titanium dioxide (E171) - 0.2%, iron dye black oxide (E172) - 3.5%, gelatin - up to 100.0%].
Description : hard gelatin capsules No. 0, capsule body - orange, lid - black. The contents of the capsule are granular powder from white with a slightly yellowish tinge to light yellow, with a weak specific odor.
Pharmacotherapeutic group:
hepatoprotective agent
ATX code : [ј05¬ј]
Pharmacological properties
Combined remedy. It has membrane stabilizing, hepatoprotective and antiviral effects.
Phosphatidylcholine (the active substance of phospholipids) is the main structural element of cellular and intracellular membranes, it is able to restore their structure and function in case of damage, providing a cytoprotective effect. It normalizes protein and lipid metabolism, prevents the loss of enzymes and other active substances by hepatocytes, restores the detoxifying function of the liver, inhibits the formation of connective tissue, reducing the risk of liver fibrosis and cirrhosis.
Glycyrrhizic acidhas an anti-inflammatory effect, suppresses the reproduction of viruses in the liver and other organs by stimulating the production of interferons, increasing phagocytosis, increasing the activity of natural killer cells. It has a hepatoprotective effect due to its antioxidant and membrane stabilizing activity. It potentiates the action of endogenous glucocorticosteroids, providing anti-inflammatory and anti-allergic effects in non-infectious liver damage.
In case of skin lesions due to the membrane-stabilizing and anti-inflammatory action of the components, it limits the spread of the process and contributes to the regression of the disease.
Pharmacokinetics
Phosphatidylcholine
More than 90% of phospholipids taken orally are absorbed in the small intestine. Most of them are cleaved by phospholipase A to 1-acetyl-lysophosphatidylcholine, 50% of which undergoes reverse acetylation to polyunsaturated phosphatidylcholine during absorption in the intestinal mucosa. Polyunsaturated phosphatidylcholine enters the bloodstream with the lymph flow, from where, mainly in the form associated with high density lipoproteins, it enters the liver. Pharmacokinetics in humans was studied using radioactively labeled dilenoleyl phosphatidylcholine - 3H (choline part) and 14C (linoleic acid residue). The maximum concentration of 3H is reached after 6-24 hours, accounting for 19.9% ??of the prescribed dose; 14C - after 4-12 hours, accounting for 27.9%. The half-life of the choline component is 66 hours, the linoleic acid residue is 32 hours.In feces, 2% H and 4.5% - C are found; in urine - 6% 3H and a minimum amount of C. Both isotopes are absorbed in the intestine by more than 90%.
Glycyrrhizic acid
After oral administration in the intestine under the influence of the ?-glucuronidase enzyme produced by bacteria of normal microflora, an active metabolite is formed from glycyrrhizic acid, ?-glycyrrhetic acid, which is absorbed into the systemic circulation. In the blood, ?-glycyrrhetic acid binds to albumin and is almost completely transported to the liver. Excretion of? -Glycyrrhetic acid occurs mainly with bile, in the residual amount - with urine.
According to experimental data, phospholipids improve the lipophilic properties of glycyrrhizic acid, increasing the intensity and rate of its absorption by more than 2 times.
Indications for use
Fatty liver degeneration (hepatosis), alcoholic, toxic, including medicinal, liver damage;
As part of the complex therapy of viral hepatitis (acute and chronic), liver cirrhosis and psoriasis.
Contraindications
Hypersensitivity to glycyrrhizic acid, phosphatidylcholine or other components of the drug;
Antiphospholipid syndrome;
Pregnancy (data on efficacy and safety are not enough);
Breastfeeding period (data on efficacy and safety are not enough);
Children under 12 years of age (efficacy and safety data are scarce).
With care .
In patients with portal hypertension. In patients with arterial hypertension. If you have these diseases, you should consult your doctor before taking the drug.
Method of administration and dosage
It is taken orally, during meals, without chewing, with a small amount of liquid.
The recommended dosage regimen for adults and children over 12 years old is 2 capsules 3 times a day. The duration of use can be up to 6 months, on average - 3 months.
Interaction with other medicinal products
Not described.
Side effect
Usually the drug Phosphogliv is well tolerated, side effects develop very rarely, according to post-registration observation, the frequency is <1/10000.
Allergic reactions : skin rash, difficulty in nasal breathing, conjunctivitis, cough.
From the side of the cardiovascular system : transient (transient) increase in blood pressure, peripheral edema.
From the digestive system : dyspepsia (belching, nausea, bloating), abdominal discomfort.
If these symptoms occur, you should stop taking the drug and consult your doctor.
Overdose
Overdose cases were not registered.
special instructions
If blood pressure rises, you should stop taking the drug and consult a doctor.
Influence on the ability to drive vehicles and mechanisms
The drug does not adversely affect the ability to drive vehicles and perform other work that requires increased concentration of attention and speed of psychomotor reactions.
Release form
Capsules.
30, 50, 100, 200 or 300 capsules in plastic containers with high pressure polyethylene or propylene lids.
10 capsules in a blister strip made of polyvinyl chloride film and aluminum foil.
1 container or 2, 3, 5 blisters together with instructions for use are placed in a carton box.
Storage conditions
Store at a temperature not exceeding 25 ? C.
Keep out of the reach of children.
Shelf life
3 years.
Do not use the drug after the expiration date.
Vacation conditions
Without recipe.